Cagrilintide powder
|
Product Name |
Cagrilintide powder |
|
CAS Number |
1415456-99-3 |
|
Appearance |
White powder |
|
Storage method |
freeze-drying at -20℃ and storage away from light |
|
Note |
For research purposes only, not for human use |
1. Mechanism of Action
Mimics amylin, a hormone co-secreted with insulin that:
Reduces appetite (via brain signaling).
Slows gastric emptying (like GLP-1 drugs).
Promotes satiety (feeling full longer).
No direct effect on insulin or glucagon, making it complementary to GLP-1 therapies.
2. Clinical Use & Research Status
Combination with Semaglutide:
CagriSema (cagrilintide + semaglutide) is in Phase 3 trials for obesity and type 2 diabetes.
Early data suggests superior weight loss (~15-17%) vs. semaglutide alone (~12%).
Standalone Use:
In trials, cagrilintide alone showed ~10-12% weight loss at higher doses.
3. Cagrilintide Powder (Research Use Only)
Not FDA-approved for human use (as of 2024).
Available as a lyophilized (freeze-dried) powder for research/lab purposes.
Typical Dosing in Studies: 2.4mg to 4.5mg once weekly (similar to Wegovy's dosing schedule).
Caution:
Not for human consumption unless in approved clinical trials.
No legal compounding or pharmacy availability yet.
4. Potential Side Effects
Most Common: Nausea, vomiting, constipation (similar to GLP-1s).
Less Common: Mild hypoglycemia (if used with insulin).
Hot Tags: cagrilintide powder, China cagrilintide powder manufacturers, suppliers, factory, obesity treatment drug, anti obesity product, weight reduction supplement, Cagrilintide-15mg, peptide for body weight loss supplement, peptide for weight loss supplement